- |||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Xeljanz (tofacitinib) / Pfizer
Clinical, Journal: New and Emerging Therapies for Pediatric Atopic Dermatitis. (Pubmed Central) - Oct 31, 2019 Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.
- |||||||||| Review, Journal: What's New in Atopic Dermatitis. (Pubmed Central) - Jul 4, 2019
Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.
- |||||||||| tralokinumab (CAT 354) / Leo Pharma, AstraZeneca
Clinical, Journal: Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. (Pubmed Central) - Jun 26, 2019 P2, P3 Further trials have assessed the ability of tralokinumab to reduce oral corticosteroid use (TROPOS; NCT02281357) and determined its mechanistic effects (MESOS; NCT02449473). An open-label study in Japanese individuals (NCT02902809) assessed the long-term safety and tolerability of tralokinumab in this population.
- |||||||||| anrukinzumab (IMA-638) / Pfizer, tralokinumab (CAT 354) / Leo Pharma, AstraZeneca
Review, Journal: The role of interleukin-13 in chronic inflammatory intestinal disorders. (Pubmed Central) - Jun 3, 2019 Failure of the anti-IL-13 monoclonal antibodies tralokinumab and anrukinzumab in UC patients in clinical trials support the absence of a role for IL-13 in UC. This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (clinicaltrials.gov) - May 23, 2019 P2, N=212, Active, not recruiting, This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool. Recruiting --> Active, not recruiting
- |||||||||| tralokinumab (CAT 354) / Leo Pharma, AstraZeneca
Biomarker, Clinical, P3 data, Journal: Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. (Pubmed Central) - May 2, 2019 P3 Tralokinumab reduced AAER in participants with severe asthma with baseline FENO 37 ppb or higher in STRATOS 1, but not in STRATOS 2. These inconsistent effects on AAER do not support a key role for interleukin 13 in severe asthma exacerbations.
- |||||||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Trial completion date, Trial primary completion date: A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata (clinicaltrials.gov) - Aug 22, 2018 P2, N=22, Completed, N=50 --> 200 Recruiting --> Completed | Trial completion date: Apr 2018 --> Nov 2017 | Trial primary completion date: Apr 2018 --> Nov 2017
|